Latest news with #IVD
Yahoo
3 days ago
- Health
- Yahoo
Kalorama Information's 2025 IVD Atlas Tracks Global Growth Hotspots, Led by China and Emerging Markets
ARLINGTON, Va., July 14, 2025 /PRNewswire/ -- Kalorama Information, a leading authority in healthcare market intelligence, announces the release of its 30-Country IVD Market Atlas, 2025 (June Update)—an in-depth strategic resource offering the most comprehensive, country-specific analysis of the in vitro diagnostics (IVD) landscape across 30 key nations. With quarterly updates throughout the year, this data-rich report equips stakeholders with timely and actionable insights to navigate the fast-evolving global diagnostics market. Timely Updates. Local Precision. Global Impact. From the U.S., China, and Germany to Vietnam, Saudi Arabia, and South Africa, Kalorama's 30-Country IVD Market Atlas delivers granular market sizing, forecasts through 2029, and segmentation across 20+ critical IVD categories, including: Molecular diagnostics (HIV, Hepatitis, Respiratory, HAI) POC testing (Pregnancy, Glucose, Infectious Disease) Immunoassays, Coagulation, Hematology, Histology Microbiology and Core Lab/Critical Care Unlike fragmented or outdated country reports, this atlas provides a single, continuously updated source for understanding demand, regulation, and competition across the globe — ideal for strategic planning, product launches, market expansion, and M&A targeting. Highlights in the 2025 June Update China emerges as the fastest-growing IVD market of the 30 countries tracked, with a projected CAGR nearing 9% through 2029—almost four times the growth of slower-expanding markets like Egypt, Russia, and Japan."China is one of the world's largest and fastest-growing IVD markets, making it a key target for major vendors seeking to offset slower growth in developed economies," said Daniel Granderson, Senior Editor at Kalorama Information. "In 2024, glucose monitoring alone accounted for over 20% of China's IVD value—and that momentum is just beginning." Countries such as Saudi Arabia, South Korea, Turkey, Vietnam, and the UAE are all forecast to exceed 5% CAGR, driven by expanding healthcare access, chronic disease burden, and tech adoption. Russia's IVD market negatively impacted due to the withdrawal of foreign businesses surrounding the Ukraine war. The rise of AI, home testing, and personalized medicine continues to reshape diagnostics delivery across nearly all regions. Who Should Read This Report? The 30-Country IVD Market Atlas is designed for: Executive leadership and strategic planners at diagnostic and medtech companies Product and portfolio managers making localization or phase-out decisions Business development teams scouting M&A and partnership opportunities Investors and private equity analysts assessing country-level growth targets Regulatory professionals tracking compliance landscapes and approval trends Get the Report Today To access the full report or schedule a custom consultation, visit:Purchase the 30-Country IVD Market Atlas, 2025 For custom research or enterprise access, contact:Sheri Davie – Sales Director, Kalorama For media inquiries, contact:Richa Singh – Vice President, Strategic & Insights About Kalorama Information A division of Science and Medicine Group, Kalorama Information has been a trusted publisher of healthcare market research for over 25 years. Its analysts specialize in in vitro diagnostics (IVD), biotechnology, medical devices, and pharmaceuticals. Kalorama is best known for its flagship title, The Worldwide Market for In Vitro Diagnostic Tests, and other authoritative benchmarks in the global medical technology space. Kalorama works in close coordination with SMG brands including BioInformatics, SDi, and IMV, enabling deep insight across diagnostics, life sciences, and imaging markets. Learn more at View original content to download multimedia: SOURCE Kalorama Information Sign in to access your portfolio
Yahoo
3 days ago
- Business
- Yahoo
India In Vitro Diagnostics (IVD) Industry Analysis & Forecast (2025-2034) Featuring Roche, Transasia Bio-Medicals, Bio-Rad Labs, BioMerieux, Sysmex, Abbott, Thermo Fisher Scientific, QIAGEN, Quidel, Danaher
The market's 6.10% CAGR reflects advances in molecular diagnostics, healthcare infrastructure expansion, and personalized medicine. Key trends include companies like Sysmex enhancing local operations and WHO expanding diabetes-related IVDs. Abbott, Qiagen, Quidel, and Danaher lead the market's innovation-driven growth. Dublin, July 21, 2025 (GLOBE NEWSWIRE) -- The "India In Vitro Diagnostics Market Report and Forecast 2025-2034" has been added to offering. The India in vitro diagnostics (IVD) market, valued at USD 2.64 billion in 2024, is foreseen to grow at a CAGR of 6.10% from 2025 to 2034, potentially reaching USD 4.77 billion by the end of the period. This growth is primarily driven by the rising prevalence of chronic diseases, government initiatives, technological advancements, and the integration of personalized medicine into healthcare systems. This report answers pivotal questions about market valuation, growth forecasts, key demand drivers, current trends, segment leadership, technology and application dominance, and challenges. It also explores key players' strategies and the impact of strategic partnerships and mergers on market dynamics. Market Overview The IVD sector in India plays a crucial role in preventive healthcare, disease management, and personalized medicine. Driven by increased healthcare awareness and technological advancements in diagnostic technologies, the market is set for significant expansion. Government efforts to enhance healthcare infrastructure and focus on early, precise diagnostics are further powering its growth. Growth Drivers The surge in chronic and non-communicable diseases (NCDs) forms a fundamental growth driver for the IVD market in India. These conditions demand early and accurate diagnosis, thereby elevating the demand for cutting-edge diagnostic technologies. According to India's Ministry of Science and Technology, NCDs account for a substantial portion of mortality and disability, necessitating improved diagnostic solutions. Market Trends Several trends are shaping the market, including the localization of operations by IVD companies and the development of disease-specific IVD solutions. For instance, Sysmex India's commitment to establishing local manufacturing facilities marks a shift towards direct operations, which enhances product availability and customer support. Additionally, the expanding scope of disease-specific diagnostics, such as the WHO's inclusion of diabetes-related tests in its prequalification scope, underscores the market's evolution towards targeted healthcare solutions. Market Segmentation The market is segmented based on products and services (reagents and kits, instruments, software and services), technology (immunodiagnostics, molecular diagnostics, clinical chemistry, among others), application (infectious diseases, diabetes, oncology, and more), end user (hospitals, diagnostic centers, point-of-care testing, etc.), and regions (Northern and Central, Southern, Eastern, Western). Reagents and Kits Segment Dominance The reagents and kits segment leads due to their fundamental role in diagnostic testing. Innovations like Cipla Limited's RT-Direct multiplex COVID-19 RT-PCR test kit highlight the segment's importance, driven by advancements in point-of-care testing technologies and the growing prevalence of chronic and infectious diseases. Key Players Major companies influencing the India IVD market include Abbott, known for its innovative molecular diagnostics; Qiagen, enhancing laboratory efficiency with upcoming automated instruments; Quidel Corporation, offering specialized immunoassays; and Danaher Corporation, addressing chronic disease challenges through advanced diagnostics. Other notable players are F. Hoffmann-La Roche Ltd, Transasia Bio-Medicals Ltd, Bio-Rad Laboratories, Inc., bioMerieux SA, Thermo Fisher Scientific Inc., and Sysmex Corporation. Key Attributes Report Attribute Details No. of Pages 250 Forecast Period 2025-2034 Estimated Market Value (USD) in 2025 $2.64 Billion Forecasted Market Value (USD) by 2034 $4.77 Billion Compound Annual Growth Rate 6.1% Regions Covered India Key Topics Covered Preface Objectives of the Study Key Assumptions Report Coverage - Key Segmentation and Scope Research Methodology Executive Summary In Vitro Diagnostics Market Overview Asia Pacific In Vitro Diagnostics Market Overview India In Vitro Diagnostics Market Overview Vendor Positioning Analysis Key Vendors Prospective Leaders Niche Leaders Disruptors India In Vitro Diagnostics Market Landscape India In Vitro Diagnostics Market: Developers Landscape India In Vitro Diagnostics Market: Product Landscape India In Vitro Diagnostics Market Dynamics Market Drivers and Constraints SWOT Analysis PESTEL Analysis Porter's Five Forces Model Key Demand Indicators Key Price Indicators Industry Events, Initiatives, and Trends Value Chain Analysis India In Vitro Diagnostics Market Segmentation (2018-2034) India In Vitro Diagnostics Market by Product & Services India In Vitro Diagnostics Market by Technology India In Vitro Diagnostics Market by Application India In Vitro Diagnostics Market by End User India In Vitro Diagnostics Market by Region Regulatory Framework Funding and Investment Analysis Analysis by Funding Instances Analysis by Type of Funding Analysis by Funding Amount Analysis by Leading Players Analysis by Leading Investors Analysis by Geography Strategic Initiatives Analysis by Partnership Instances Analysis by Type of Initiatives Analysis by Joint Ventures Analysis by Leading Players Analysis by Geography Supplier Landscape Market Share Analysis (Top 5 Companies) F. Hoffmann-La Roche Ltd. Transasia Bio-Medicals Ltd. Bio-Rad Laboratories, Inc. BioMerieux SA Sysmex Corporation Abbott Thermo Fisher Scientific Inc. QIAGEN Quidel Corporation Danaher Corporation India In Vitro Diagnostics Market - Distribution Model (Additional Insight) Overview Potential Distributors Key Parameters for Distribution Partner Assessment Key Opinion Leaders (KOL) Insights (Additional Insight) For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
India In Vitro Diagnostics (IVD) Industry Analysis & Forecast (2025-2034) Featuring Roche, Transasia Bio-Medicals, Bio-Rad Labs, BioMerieux, Sysmex, Abbott, Thermo Fisher Scientific, QIAGEN, Quidel, Danaher
The market's 6.10% CAGR reflects advances in molecular diagnostics, healthcare infrastructure expansion, and personalized medicine. Key trends include companies like Sysmex enhancing local operations and WHO expanding diabetes-related IVDs. Abbott, Qiagen, Quidel, and Danaher lead the market's innovation-driven growth. Dublin, July 21, 2025 (GLOBE NEWSWIRE) -- The "India In Vitro Diagnostics Market Report and Forecast 2025-2034" has been added to offering. The India in vitro diagnostics (IVD) market, valued at USD 2.64 billion in 2024, is foreseen to grow at a CAGR of 6.10% from 2025 to 2034, potentially reaching USD 4.77 billion by the end of the period. This growth is primarily driven by the rising prevalence of chronic diseases, government initiatives, technological advancements, and the integration of personalized medicine into healthcare systems. This report answers pivotal questions about market valuation, growth forecasts, key demand drivers, current trends, segment leadership, technology and application dominance, and challenges. It also explores key players' strategies and the impact of strategic partnerships and mergers on market dynamics. Market Overview The IVD sector in India plays a crucial role in preventive healthcare, disease management, and personalized medicine. Driven by increased healthcare awareness and technological advancements in diagnostic technologies, the market is set for significant expansion. Government efforts to enhance healthcare infrastructure and focus on early, precise diagnostics are further powering its growth. Growth Drivers The surge in chronic and non-communicable diseases (NCDs) forms a fundamental growth driver for the IVD market in India. These conditions demand early and accurate diagnosis, thereby elevating the demand for cutting-edge diagnostic technologies. According to India's Ministry of Science and Technology, NCDs account for a substantial portion of mortality and disability, necessitating improved diagnostic solutions. Market Trends Several trends are shaping the market, including the localization of operations by IVD companies and the development of disease-specific IVD solutions. For instance, Sysmex India's commitment to establishing local manufacturing facilities marks a shift towards direct operations, which enhances product availability and customer support. Additionally, the expanding scope of disease-specific diagnostics, such as the WHO's inclusion of diabetes-related tests in its prequalification scope, underscores the market's evolution towards targeted healthcare solutions. Market Segmentation The market is segmented based on products and services (reagents and kits, instruments, software and services), technology (immunodiagnostics, molecular diagnostics, clinical chemistry, among others), application (infectious diseases, diabetes, oncology, and more), end user (hospitals, diagnostic centers, point-of-care testing, etc.), and regions (Northern and Central, Southern, Eastern, Western). Reagents and Kits Segment Dominance The reagents and kits segment leads due to their fundamental role in diagnostic testing. Innovations like Cipla Limited's RT-Direct multiplex COVID-19 RT-PCR test kit highlight the segment's importance, driven by advancements in point-of-care testing technologies and the growing prevalence of chronic and infectious diseases. Key Players Major companies influencing the India IVD market include Abbott, known for its innovative molecular diagnostics; Qiagen, enhancing laboratory efficiency with upcoming automated instruments; Quidel Corporation, offering specialized immunoassays; and Danaher Corporation, addressing chronic disease challenges through advanced diagnostics. Other notable players are F. Hoffmann-La Roche Ltd, Transasia Bio-Medicals Ltd, Bio-Rad Laboratories, Inc., bioMerieux SA, Thermo Fisher Scientific Inc., and Sysmex Corporation. Key Attributes Report Attribute Details No. of Pages 250 Forecast Period 2025-2034 Estimated Market Value (USD) in 2025 $2.64 Billion Forecasted Market Value (USD) by 2034 $4.77 Billion Compound Annual Growth Rate 6.1% Regions Covered India Key Topics Covered Preface Objectives of the Study Key Assumptions Report Coverage - Key Segmentation and Scope Research Methodology Executive Summary In Vitro Diagnostics Market Overview Asia Pacific In Vitro Diagnostics Market Overview India In Vitro Diagnostics Market Overview Vendor Positioning Analysis Key Vendors Prospective Leaders Niche Leaders Disruptors India In Vitro Diagnostics Market Landscape India In Vitro Diagnostics Market: Developers Landscape India In Vitro Diagnostics Market: Product Landscape India In Vitro Diagnostics Market Dynamics Market Drivers and Constraints SWOT Analysis PESTEL Analysis Porter's Five Forces Model Key Demand Indicators Key Price Indicators Industry Events, Initiatives, and Trends Value Chain Analysis India In Vitro Diagnostics Market Segmentation (2018-2034) India In Vitro Diagnostics Market by Product & Services India In Vitro Diagnostics Market by Technology India In Vitro Diagnostics Market by Application India In Vitro Diagnostics Market by End User India In Vitro Diagnostics Market by Region Regulatory Framework Funding and Investment Analysis Analysis by Funding Instances Analysis by Type of Funding Analysis by Funding Amount Analysis by Leading Players Analysis by Leading Investors Analysis by Geography Strategic Initiatives Analysis by Partnership Instances Analysis by Type of Initiatives Analysis by Joint Ventures Analysis by Leading Players Analysis by Geography Supplier Landscape Market Share Analysis (Top 5 Companies) F. Hoffmann-La Roche Ltd. Transasia Bio-Medicals Ltd. Bio-Rad Laboratories, Inc. BioMerieux SA Sysmex Corporation Abbott Thermo Fisher Scientific Inc. QIAGEN Quidel Corporation Danaher Corporation India In Vitro Diagnostics Market - Distribution Model (Additional Insight) Overview Potential Distributors Key Parameters for Distribution Partner Assessment Key Opinion Leaders (KOL) Insights (Additional Insight) For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-07-2025
- Business
- Yahoo
Saudi Arabia In-Vitro Diagnostics Market Report 2025-2030 Featuring Abbott, BD, Bio-Rad Laboratories, Biomerieux, Danaher, Nihon Kohden, Roche, Siemens Healthineers, Sysmex, Thermo Fischer Scientific
Saudi Arabia's in-vitro diagnostics market is set to grow from USD 734.7M in 2024 to USD 932.3M by 2030, driven by a rising elderly population and chronic disease prevalence. Saudi Arabia leads the GCC region in IVD, benefiting from government initiatives like Vision 2030 and healthcare sector advances. Dublin, July 16, 2025 (GLOBE NEWSWIRE) -- The "Saudi Arabia In-Vitro Diagnostics (IVD) Market (By Segment, Application, Product, End User), Size, Share, Major Deals, Key Company Profiles, Revenue, Recent Developments - Forecast to 2030" report has been added to offering. The Saudi Arabia in-vitro diagnostics market is predicted to reach USD 932.3 Million by 2030, from USD 734.7 Million in 2024. Saudi Arabia is the largest market for in-vitro diagnostics in the GCC region. As in other countries, Saudi Arabia is facing the challenges of fighting infectious diseases, including HBV, TB, HC, V, and HIV, as well as various chronic diseases and cancer. In-vitro diagnostics play an important role in the detection of infectious and chronic diseases. The rising geriatric population and the high burden of chronic and infectious diseases propel the growth of Saudi Arabia's in-vitro diagnostics market, as these chronic disorders can be diagnosed and monitored using in-vitro diagnostics (IVD) products. Furthermore, the Saudi Arabian government is taking several initiatives to improve the healthcare sector in the country. For instance, under Vision 2030, the Saudi Arabian Government plans to invest over USD 65 Billion to develop the country's healthcare infrastructure. The government has set the target of privatizing 290 hospitals and 2,300 primary health centers by 2030. Also, the government seeks to improve the country's healthcare sector by adopting digital information systems. Recent Developments In February 2025, ABL Diagnostics announced that manufacture and commercialize a full range of UltraGene PCR tests acquired from its parent company, Advanced Biological Laboratories. In October 2024, Abbott Molecular was granted emergency use authorization for its Alinity m MPXV assay for the diagnosis of mpox. It is a real-time PCR test that will allow faster detection of the virus. In January 2024, bioMerieux announced the acquisition of LUMED, a software company that has developed a clinical decision support system to help hospitals optimize antimicrobial prescriptions and monitor healthcare-associated infections. In August 2023, Sysmex Corporation announced an expansion of the Global Business Partnership Agreement (GBPA) with Roche Diagnostics International Ltd. Technology Key Takeaways On a technology basis, Immunoassay and Clinical Chemistry are the dominating segments of the Saudi Arabia IVD market. Together, they contributed nearly 58 percent to the total Saudi Arabia IVD market in 2024. Both these segments are likely to maintain their leading position over the forecast period. Molecular Diagnostics captured over 10 percent share of the Saudi Arabia IVD market in 2024. POCT and SMBG segments are competing closely to grab the maximum market share of the pie. POCT is transforming diagnostic practices through its convenience and efficiency. The growth of the hematology market is attributed to factors such as the increasing incidences of blood disorders, the growing adoption of automated hematology instruments by diagnostic laboratories, the emergence of high-throughput hematology analyzers, and the introduction of technologically advanced hematology instruments. Application Key Takeaways On the basis of application, Infectious diseases and Diabetes are the leading segments of the Saudi Arabia IVD market. Together, they contributed over 55 percent to the total Saudi Arabia IVD market in 2024. The Saudi Government has set a goal to increase life expectancy from 75 to 80 years of age. This will be achieved primarily by addressing the disease burden of noncommunicable diseases in the country, such as cardiovascular disease (CVD). The oncology application segment held the 3rd highest share of the Saudi Arabia IVD market in 2023, followed by cardiovascular diseases. Autoimmune Diseases was responsible for a single digit share of the Saudi Arabia IVD market in 2024, while Nephrology held the least share of the Saudi Arabia IVD market. Product Key Takeaways Reagents controlled the highest share of the Saudi Arabia IVD market in 2024, and are expected to remain dominant over the forecast period, since reagents are a vital part of every in-vitro diagnostics test. The instruments segment was responsible for over a quarter of the Saudi Arabia IVD market in 2024. The introduction of advanced instruments offers an excellent avenue for the segment's growth. The software and services held the least share of the Saudi Arabian IVD market. End User Key Takeaways Government Labs & Hospitals held the largest share of the Saudi Arabia IVD market in 2024, owing to the large volume of diagnostic tests carried out in hospitals and the rising volumes of Class II and Class III in vitro diagnostics medical devices that are being readily used for diagnostic testing. Private Labs & Hospitals contributed nearly a quarter to the overall Saudi Arabia IVD market. Saudi Arabian government has set the target of privatizing 290 hospitals and 2,300 primary health centers by 2030, under the Saudi Vision 2030 Plan. Key Company Profiles Abbott Becton Dickinson and Company Bio-Rad Laboratories, Inc Biomerieux SA Danaher Corporation Nihon Kohden Corporation Roche Siemens Healthineers Sysmex Corporation Thermo Fischer Scientific Inc. By Segment - Saudi Arabia IVD Market and Forecast Immunoassay Clinical Chemistry Hematology Coagulation/Hemostasis Microbiology Molecular Diagnostic Self-Monitoring of Blood Glucose (SMBG) Point of Care Testing (POCT) Others By Application - Saudi Arabia IVD Market and Forecast Infectious Diseases Cardiovascular Diseases Diabetes Oncology Nephrology Autoimmune Diseases Others By Product - Saudi Arabia IVD Market and Forecast Reagents Instruments Software and Services By End User - Saudi Arabia IVD Market and Forecast Government Labs & Hospitals Private Labs & Hospitals Others For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
Yahoo
03-07-2025
- Business
- Yahoo
Qiagen Teams With Gencurix to Expand Digital PCR Cancer Assays
Qiagen N.V. (NYSE:QGEN) ranks among the best CRISPR stocks to buy. Qiagen N.V. (NYSE:QGEN) and Gencurix announced a collaboration on June 18 to provide oncology assays for Qiagen's QIAcuityDx digital PCR platform. The collaboration will focus on developing multiplex cancer assays for use in liquid and tissue biopsies. As the authorized manufacturer, Gencurix will create a number of cancer tests while striving to obtain IVD regulatory clearances. Following approval, Qiagen's global commercial infrastructure will be used for marketing the assays. The collaboration makes use of QIAGEN's QIAcuityDx platform, a member of the QIAcuity family of digital PCR technologies, which by the end of 2024 had achieved over 2,700 total placements. Furthermore, Qiagen N.V. (NYSE:QGEN) recently concluded the acquisition of Genoox for $70 million, with possible extra milestone payments, in order to improve its capacity for genetic data analysis. Qiagen's Digital Insights suite now incorporates Genoox's Franklin platform. A global leader in Sample to Insight solutions, Qiagen N.V. (NYSE:QGEN) offers tools for extracting and analyzing proteins, RNA, and DNA from a variety of samples. While we acknowledge the potential of QGEN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
